Pharmalex Nordic ApS: Financial statements 2018
CVR: 37541540
Source: annual report 2018, Danish Business Authority
01/01/2018 – 31/12/2018
Pharmalex Nordic ApS (CVR 37541540) has filed annual accounts for 2018. In 2018, the company reported a gross profit of DKK 1,890,960 and a net result of DKK 891,680 compared with DKK 494,960 the year before. That is an increase of 1,797.4% compared with the year before. Equity in the 2018 report amounted to DKK 22,197,368. The solvency ratio was 37.4%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 1,890,960
- Profit/Loss
- DKK 891,680
- Equity
- DKK 22,197,368
- Total Assets
- DKK 59,397,213
- Employees
- 1
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2018
Pharmalex Nordic ApS has published its annual report for 2017. Gross profit came to DKK 99,661, and the net result was DKK 494,960.
As of March 5, 2018, Solveig Blomvik has stepped down as director of Pharmalex Nordic ApS.
As of February 21, 2018, Anette Langgaard Jacobsen has stepped down as director of Pharmalex Nordic ApS.
About Pharmalex Nordic ApS
Pharmalex Nordic ApS is a Danish company of the type Anpartsselskab based in Kongens Lyngby, founded in 2016. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Åsa Pihlblad and Christopher Gauglitz. The company is owned by AmerisourceBergen International B.V.. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK 3,533,803 and a net result of DKK 1,709,691 compared with DKK -88,447,652 the year before. Equity in the 2025 report amounted to DKK -45,957,544.